A detailed history of Cullen/Frost Bankers, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 8 shares of BGNE stock, worth $1,776. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8
Holding current value
$1,776
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$143.93 - $224.51 $1,151 - $1,796
8 New
8 $1,000
Q1 2023

May 05, 2023

BUY
$215.53 - $274.5 $3,664 - $4,666
17 New
17 $3,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.